Specialty Pharma Journal Specialty, Precision & Technology
Athens, Greece, 28 September 2018 – Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.1 There are currently no approved once-weekly treatments for growth hormone deficiency. The REAL …
Tag Archives: Novo Nordisk
September, 2018
August, 2018
-
17 August
Novo Nordisk Acquires Ziylo, Gaining Innovative Technology Platform that Could Accelerate Development of New Diabetes Treatment
BRISTOL and COPENHAGEN, 17 August 2018 - Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology – …
January, 2018
-
8 January
Ablynx Rejects Novo Nordisk’s $3.1 Billion Acquisition Proposal
GHENT, Belgium, 8 January 2018 – Ablynx NV (Euronext Brussels and Nasdaq: ABLX) (“Ablynx” or the “Company”) today confirmed that on December 22, 2017 it received an unsolicited conditional proposal from Novo Nordisk A/S (CSE: NOVO B) (NYSE:NVO) (“Novo Nordisk”) to acquire all of the outstanding shares of Ablynx for …
June, 2017
-
1 June
FDA Approves New Novo Nordisk Hemophilia B Treatment
PLAINSBORO, N.J., May 31, 2017 /PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. Hemophilia B is a chronic and inherited bleeding …
November, 2016
-
22 November
Novo Nordisk’s Diabetes Drug Xultophy Wins FDA Approval
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ — Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy®100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection). Xultophy® 100/3.6 is a once-daily, combination of Tresiba® (insulin degludec …
March, 2015
-
27 March
Novo Nordisk Announces Plans to Resubmit Rejected Insulin to the FDA
Novo Nordisk A/S announced its decision to resubmit its marketing applications for diabetes drugs Tresiba and Ryzodeg to US health regulators. In 2013, the company submitted marketing applications to the US Food and Drug Administration (FDA) for basal insulin product Tresiba and combination therapy Ryzodeg. Even after an advisory committee …
-
24 March
Bristol-Myers Squibb Buys Rights to Novo Nordisk’s Autoimmune Program
Bristol-Myers Squibb (BMS) is acquiring rights to Novo Nordisk’s early-stage immune system research program, which Novo Nordisk is divesting as it focuses on diabetes and obesity. The company announced today that it has signed an agreement with Novo Nordisk, under which BMS will acquire an exclusive global license to a …